| Nov 15 |
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
|
| Nov 14 |
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
|
| Nov 14 |
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
|
| Nov 11 |
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024
|
| Oct 24 |
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
|
| Oct 22 |
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
|
| Oct 16 |
Soligenix Invited to Present at Upcoming Investor Conferences
|
| Oct 7 |
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
|
| Oct 3 |
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development…
|
| Oct 3 |
Soligenix enters partnership with Sterling Pharma
|
